沙利度胺对弥漫大B细胞淋巴瘤患者血清血管内皮生长因子水平的影响及临床意义

目的:观察沙利度胺联合CHOP方案治疗弥漫大B细胞淋巴瘤(DLBCL)患者前后血清血管内皮生长因子(VEGF)水平的变化及临床意义.方法:40例DLBCL患者随机分为2组,各20例,化疗组CHOP方案常规化疗;联合组CHOP方案常规化疗+沙利度胺治疗,沙利度胺50 mg/次,每天早晚各1次,第1～28天给药.4周1个疗程,治疗2个周期后比较疗效.采用酶联免疫法检测40例患者治疗前、后血清VEGF的水平.结果:联合组有效率(CR+ PR)为80％,化疗组有效率60％.差异有统计学意义(P＜0.05).2组治疗前血清VEGF水平比较差异无统计学意义(P＞0.05);化疗组化疗前后血清VEGF水平比较差异无统计学意义(P＞0.05),联合组治疗后血清VEGF水平较化疗前明显下降(P＜0.05).结论:沙利度胺联合CHOP化疗能改善DLBCL患者的有效率;沙利度胺能抑制肿瘤细胞VEGF的产生,从而降低血清VEGF的水平.     

再生育子痫前期患者血清脂联素、肝细胞生长因子、胎盘生长因子和杀伤细胞抑制性受体表达水平的变化

目的 观察再生育子痫前期患者血清脂联素、肝细胞生长因子(HGF)、胎盘生长因子(PLGF)和杀伤细胞抑制性受体(KIR)表达水平的变化.方法 纳入2016年2月至2019年1月承德医学院附属医院妇产科就诊的单胎再生育孕妇,将子痫前期的单胎再生育孕妇106例纳入研究,列为子痫前期组.另纳入同时期就诊的妊娠期高血压(PIH...     

血管内皮生长因子在肝细胞癌中的表达及其临床意义

本文对肝细胞癌(HCC)中血管内皮生长因子(VEGF)的表达情况进行观察. 1 对象与方法 1.1 研究对象 收集我院2004年3月至2007年3月住院病例50例,其中男36例,女14例,年龄51～86岁,平均77岁.     

封闭负压引流术结合重组人表皮生长因子治疗老年性糖尿病溃疡创面疗效分析

目的 探讨封闭负压引流术(VSD)结合重组人表皮生长因子(rhEGF)治疗老年性糖尿病溃疡创面的临床疗效.方法 选择2017年8月—2019年6月64例老年性糖尿病慢性溃疡创面患者为研究对象,随机分成观察组32例与对照组32例,观察组采用封闭负压引流术+重组人表皮生长因子的方法,对照组采用封闭负压引流术+常规换药的方法...     

原发性肺癌患者血清血管内皮细胞生长因子检测的临床意义

新近发现 ,肿瘤血管形成与肿瘤浸润转移及预后密切相关 ,肿瘤血管形成受血管生成抑制因子和血管形成促进因子的共同调节 ,其中血管内皮细胞生长因子 ( CVEGF)是最有效和特异的生长因子。2 0 0 0年 3月至 2 0 0 2年 2月 ,我们对原发性支气管肺癌患者进行了血清 VEGF含量检测 ,以探讨血清VEGF含量与肺癌的关系。现报告如下。1　资料与方法1 .1　临床资料　选取山东省肿瘤医院 87例手术患者 ,男 65例 ,女 1 4例 ;年龄 32～ 76岁 ,平均 ( 5 7±1 7)岁。有吸烟史 40例 ,嗜酒 31例 ;原发性肺癌 79例 ,肺良性实质性病变 8例 ( 4例炎性假瘤 ,2…     

转化生长因子-β1血小板源性生长因子和结缔组织生长因子在矽肺病患者血清中的表达及意义

我们对58例矽肺病患者血清中转化生长因子-β1(TGF-β1)、血小板源性生长因子(PDGF)、结缔组织生长因子(CTGF)进行了检测和分析,探讨TGF-β1、PDGF、CTGF在矽肺病发生、发展中的变化及其意义.     

表皮生长因子和胃泌素在胃癌组织中的表达及意义

目的 探讨表皮生长因子(EGF)和胃泌素(GAS)在胃癌组织中的表达,及其相互关系与意义.方法 选取我院2003年1月～2009年12月经病理确诊的胃癌(GC)70例,慢性浅表性胃炎(CSG)25例,经过纳入标准及排除标准的筛选而作为研究对象.采用免疫组织化学Envision方法,检测EGF、GAS在各组胃黏膜组织中的...     

多发性骨髓瘤患者血清肿瘤特异性生长因子水平及其临床意义

肿瘤特异性生长因子(TSGF)是目前研究较多的肿瘤生物学标志物，为恶性肿瘤形成及生长时促使肿瘤及周边毛细血管大量增殖的因子，其检测对恶性肿瘤的诊断及治疗有特异性指导意义。多发性骨髓瘤(MM)是一种血液系统恶性肿瘤，有关其TSGF的表达水平少见报道。2001年2月至2004年1月，我们对18例MM患者治疗前后的血清TSGF进行了检测，以探讨其表达特点及临床意义。     

血管内皮生长因子+405G/C基因多态性与AMI的相关性

目的:分析血管内皮生长因子(VEGF) 405G/C基因多态性与急性心肌梗死(AMI)的相关性.方法:选取我院2018年1月-2019年12月收治的124例AMI患者设为AMI组.同时选取120例体检的正常健康人群作为对照组.采集血样提取DNA,利用聚合酶链式反应(PCR)、酶切反应及琼脂糖凝胶电泳检测VEGF基因40...     

低分子肝素辅助治疗对胎儿生长受限患者胎盘超微结构及血管内皮生长因子表达的影响

目的 探讨低分子肝素辅助治疗对胎儿生长受限(FGR)患者胎盘超微结构及血管内皮生长因子(VEGF)表达的影响.方法 选取2020年1月至2021年1月我院收治的FGR患者80例为研究对象,随机分成实验组与对照组,每组40例.对照组患者给予常规治疗,实验组患者在对照组的基础上给予低分子肝素治疗,治疗10 d为1个疗程,共...     

非霍奇金淋巴瘤患者sVEGF和sbFGF水平的变化及临床意义

目的:研究非霍奇金淋巴瘤(NHL)患者血清血管内皮生长因子(sVEGF)及血清碱性成纤维细胞生长因子(sbFGF)水平与临床特征的关系,探索其临床意义.方法:ELISA法检测36例不同病期NHL患者sVEGF、sbFGF水平,并收集临床资料,进行统计分析.结果:NHL患者sVEGF、sbFGF水平明显高于对照组(均P＜...     

Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma

Therapeutic approaches for non-Hodgkin's lymphoma (NHL) are currently based on the International Prognostic Index (IPI). Research on biological prognostic factors has been actively pursued in recent years, with serum vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) being identified as prognostic factors for NHL. Here, we determined that serum VEGF and IL-6 levels are independent prognostic factors for aggressive lymphoma. Compared with normal controls, serum VEGF and IL-6 levels were significantly higher in patients with aggressive lymphoma or adult T-cell leukemia/lymphoma. Furthermore, overall and disease-free survival rates for patients with high levels of VEGF or IL-6 were significantly poorer than for patients with low levels. In addition, the prognosis for patients with high levels of both serum VEGF and IL-6 was significantly poorer than that for patients with high levels of either VEGF or IL-6 or with low levels of both VEGF and IL-6. Multivariate analyses of a variety of prognostic factors, including the five IPI factors, revealed that serum VEGF and IL-6 were both independent prognostic factors for overall survival of aggressive lymphoma. Therefore, a combination of VEGF and IL-6 represents a useful prognostic factor for aggressive lymphoma.     

Angiogenic and coagulation-fibrinolysis factors in non Hodgkin's lymphoma

High serum VEGF and bFGF levels are independent prognostic factors of poor prognosis in NHL patients. There is growing evidence that both angiogenesis and haemostatic aberrancies are integral parts of the pathobiology of cancer growth and dissemination. The purpose of the study was: (a) to analyze relations of VEGF and bFGF serum levels, fibrinogen and D-dimer plasma levels with lymphoma Ann Arbor Staging System (AASS) and International Prognostic Index (IPI) and, (b) to evaluate correlations between serum levels of angiogenic cytokines and plasma levels of coagulation-fibrinolysis factors in 52 previously untreated NHL patients included to the study. The control group consisted of 23 healthy volunteers. Serum VEGF, bFGF and plasma D-dimer levels were measured by enzyme-linked immunosorbent assay (ELISA). Plasma levels of fibrinogen were determined on Behring Coagulation System (BCS) equipment. In lymphoma group serum VEGF and bFGF levels were significantly higher than in the control. Differences in concentrations of VEGF, bFGF between II, III and IV stage of disease acc. AASS were not statistically significant. Plasma levels of fibrinogen and D-dimer were elevated in lymphoma patients when compared with the control. Fibrinogen plasma levels were similar in all stages. The D-dimer level was significantly higher in patients with IV stage in comparison to stage II and III. Statistically significant differences of VEGF and bFGF serum levels were observed only between intermediate/high and high risk groups acc. IPI. Fibrinogen plasma levels were significantly higher in high risk group than in low risk group. D-dimer plasma levels were significantly higher in high risk group than in low risk group and low/intermediate group. We observed positive correlation between serum level of VEGF and plasma level of fibrinogen, and between serum level of bFGF and plasma level of fibrinogen. There was also negative correlation between serum level of VEGF and plasma level of D-dimer, and between serum level of bFGF and plasma level of D- dimer. Our study indicates that D-dimer level, but not VEGF, bFGF and fibrinogen correlates with AASS and IPI in NHL patients. Significant correlations between levels of VEGF/bFGF and fibrinogen/D-dimer suggest specific interactions between angiogenic and coagulation-fibrinolysis system.     

Vascular endothelial growth factor (VEGF) serum concentration in non-Hodgkin's lymphoma patients

Non-Hodgkin's lymphomas (nHL) is a heterogenous group of lymphoid malignancies with different patterns of behaviour and response to treatment. International Prognostic Index (IPI) is commonly used to predict outcome of treatment in nHL. There are several reports that vascular endothelial growth factor (VEGF), the most potent inducer of angiogenesis, may have prognostic significance in nHL. The aim of the study was to evaluate the serum level of VEGF as a marker of angiogenesis in 35 patients with B-cell nHL compared with control group of 14 healthy people. Moreover, in nHL group VEGF serum level was correlated with IPI risk factors. VEGF serum level was evaluated by ChemiKine sandwich ELISA kit (Chemicon International). VEGF serum level was significantly higher in nHL group than in the control, 193.78 pg/ml +/- 6.82 SEM and 31.51 +/- 1.67 SEM respectively. In nHL group a positive correlation was found between increased VEGF serum level and serum lactate dehydrogenase level. The levels of VEGF were not significantly different in agressive or indolent nHL patients. VEGF serum level is increased in active lymphoma. This observation may have prognostic and clinical significance and provides rationale for use antiangiogenic agents in nHL therapy.     

Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma

Angiogenesis is a crucial process in growth and progression of cancer and there is growing evidence that neovascularisation is important in hematological malignancies. Since an increased angiogenic potential has been identified in multiple myeloma, we simultaneously measured circulating serum levels of the cytokines bFGF, VEGF, HGF and IL-6 by ELISA in 67 patients with multiple myeloma or monoclonal gammopathies of undetermined significance (MGUS) and in 20 controls. Median values of bFGF were 4.7 pg/ml in healthy volunteers, 6.2 in MGUS, 6.3 in myeloma stage I, 13.4 in stage II and 21.7 in stage III. Myeloma patients had significantly higher bFGF serum levels than controls (p<0.001). Pretreatment bFGF levels differed significantly in the Salmon and Durie stages I-III (p=0.02) and were significantly elevated in stage II-III compared to stage I myeloma (p=0.02). In patients responding to chemotherapy according to the CLMTF criteria, a significant decrease in serum bFGF, VEGF and HGF levels occurred (median pretreatment values for bFGF 23.9 pg/ml, post-treatment 6.5 pg/ml; p<0.001, for VEGF 223 pg/ml versus 105 pg/ml; p=0.02 and for HGF 1429 pg/ml versus 1077 pg/ml; p=0.02, respectively). In 11 patients who did not achieve a remission, there was no significant decrease in bFGF, VEGF and HGF levels. These data show that myeloma in stages II and III is associated with an increase in serum bFGF concentrations and give the first report that effective chemo-therapy is accompanied by a significant decrease in the angiogenic factors bFGF, VEGF and HGF, while no decrease of these factors could be found in nonresponders.     

三维适形放疗对食管癌患者的临床疗效观察及血清血管内皮生长因子的变化

目的探讨三维适形放疗(3DCRT)对食管癌患者的临床疗效及血管内皮生长因子(VEGF)的变化水平。方法选取2011年7月-2013年7月十堰市太和医院收治的75例食管癌患者作为研究组,另选体检中心体检的健康人群50例作为对照组。食管癌患者行3DCRT,评价患者的疗效及安全性;采用酶联免疫吸附试验双抗体夹心法检测两组血清VEGF的变化水平,探讨其在放疗中的意义。结果食管癌患者放疗前后血清VEGF水平均显著高于对照组,组间相比,差异有统计学意义(P0.05);食管癌患者放疗4周、放疗后1周血清VEGF水平较放疗前明显降低,差异具有统计学意义(P0.05);放疗有效组放疗4周及放疗后1周血清VEGF水平显著低于放疗前,差异具有统计学意义(P0.05);无效组放疗前后血清VEGF水平相比,差异无统计学意义(P0.05)。结论 3DCRT治疗食管癌疗效确切,不良反应低;VEGF可以作为评估、预测放疗敏感性的生化指标,在食管癌的治疗和预后中有重要意义。     

Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma

Circulating inflammatory cytokines have a prognostic impact independent of the information provided by the International Prognostic Index (IPI) in diffuse large B-cell lymphoma (DLBCL). The present study characterized prognostic cytokines in relation to stage-specific B-cell differentiation antigens and bcl-2 protein expression, assessed by immunohistochemistry in de novo DLBCL. Serum levels of interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF-alpha) were found to be significantly lower in patients with a germinal centre (GC) phenotype (co-expression of bcl-6 and CD10) compared with the non-GC phenotype. IL-6 and TNF-alpha levels were significantly elevated in patients expressing bcl-2 protein. Serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) were not associated with the GC phenotype. On the contrary, both VEGF and bFGF were strongly correlated to bcl-2 expression. In survival analysis, IPI score remained the most important independent prognostic factor. However, IL-6 and VEGF, combined with non-GC phenotype and bcl-2 positivity, respectively, had a similar independent prognostic power as the IPI. In conclusion, our data suggest that inflammatory cytokines are differently distributed in the GC and non-GC phenotypes and correlate to bcl-2 expression. Combining these biomarkers may add to the prognostic information given by clinical variables in the IPI alone.     

不同海拔对AECOPD患者治疗前后血清bFGF表达的影响及意义

目的探讨不同海拔环境对慢性阻塞性肺疾病急性加重期（AECOPD）患者治疗前后血清中碱性成纤维细胞生长因子（bFGF）表达的影响和意义,及血清中bFGF的变化情况与FEV1／FVC％、FEV1％Pred的相互关系。方法采用酶联免疫吸附测定（ELISA）法测定两个地区AECOPD患者及健康对照组血清bFGF的含量,并行肺功能检查,统计分析检测数据。结果①两个地区AECOPD患者治疗前后血清bFGF水平均高于健康对照组,AECOPD患者治疗后bFGF水平较治疗前下降,且平原地区AECOPD患者治疗后血清bFGF下降程度稍高于中度海拔地区;平原地区健康对照组血清bFGF含量稍低于中度海拔地区健康对照组,差异有统计学意义（P〈0．05）;②分别比较两个地区AECOPD患者治疗前后血清bFGF含量,差异无统计学意义;③两个地区AECOPD患者治疗前后FEV1／FVC％、FEVl％Pred均明显低于对照组,治疗后FEV1／FVC％、FEV1％Pred较治疗前有所升高,差异有统计学意义（P〈0．05）;两个地区各组肺功能观察指标结果比较无统计学意义;④AECOPD患者血清中bFGF表达水平与FEV1／FVC％、FEVl％Pred无相关性。结论①两个地区AECOPD患者治疗前后血清bFGF水平均较对照组高,提示bFGF参与了COPD发病进程;②中度海拔低氧可刺激健康人血清bFGF表达,但对AECOPD患者的表达无影响,提示bFGF、低氧与慢性阻塞性肺疾病发病率、病情严重程度无明显关系;⑧血清bFGF水平对FEV、／FVC、FEV、％Pred无明显影响。     

Vascular endothelial growth factor levels in active pulmonary tuberculosis

BACKGROUND: Vascular endothelial growth factor (VEGF) is a mediator with potent angiogenic, mitogenic, and vascular permeability-enhancing activities that are specific for endothelial cells. Intense angiogenesis has been found in active pulmonary tuberculosis lesions. OBJECTIVES: To determine whether active pulmonary tuberculosis is associated with increased serum levels of VEGF compared with inactive tuberculosis and VEGF levels in healthy subjects, and to assess the changes in serum VEGF levels before and after therapy. DESIGN: Prospective clinical study. SETTING: Chest clinic of a university hospital, Eskisehir, Turkey. PATIENTS AND MEASUREMENTS: Serum VEGF levels of 44 patients with active pulmonary tuberculosis, 24 patients with inactive pulmonary tuberculosis, and 20 healthy subjects were determined. RESULTS: VEGF levels were increased in active pulmonary tuberculosis patients (mean [+/- SD] VEGF level, 598.03 +/- 298.25 pg/mL) compared to both inactive pulmonary tuberculosis patients (mean VEGF level, 296.98 +/- 115.31 pg/mL) and control subjects (mean VEGF level, 339.67 +/- 74.65 pg/mL). The increase in VEGF level observed in patients with active tuberculosis was statistically significant when compared with levels in two other groups (p < 0.001 for both). Serum VEGF levels were statistically different before treatment and after treatment in 10 patients who were observed from diagnosis to the end of treatment (p < 0.01). CONCLUSIONS: Increased serum VEGF levels may be an indicator of active pulmonary tuberculosis, since levels were higher in patients with active pulmonary tuberculosis and were lower after successful treatment. The role of VEGF-mediated angiogenesis in the pathogenesis and progression of pulmonary tuberculosis lesions should be further elucidated.     

肝细胞癌患者肝动脉化疗栓塞术前后血清TGFβ1、VEGF、bFGF浓度变化

目的：观察肝细胞癌患者肝动脉化疗栓塞术（TACE）前后血清转化生长因子（TGFβ1）、血管内皮生长因子（VEGF）和碱性成纤维细胞生长因子（bFGF）的浓度变化。方法：随机选择64例经病理确诊的肝细胞癌（HCC）患者,按照单纯随机抽样法均分为实验组和对照组,两组患者治疗药物相同,实验组患者行TACE术,对照组患者静脉注射化疗药物。用双抗体夹心酶联免疫吸附试验法检测两组患者TACE术前3天和术后两周血清TGFβ1、VEGF、bFGF浓度。结果：治疗后两周患者血清TGFβ1、VEGF、bFGF浓度均升高;与治疗前比较,差异有显著性意义（P〈0.05）。结论：TACE的远期疗效欠佳,可能是其引起HCC患者血清TGFβ1、VEGF、bFGF过表达,导致肿瘤血管增生、侧枝循环形成以及机体的免疫反应被抑制。